Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Francque, Sven; Szabo, Gyongyi; Abdelmalek, Manal F; Byrne, Christopher D; Cusi, Kenneth; Dufour, Jean-François; Roden, Michael; Sacks, Frank; Tacke, Frank (2021). Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nature reviews - gastroenterology & hepatology, 18(1), pp. 24-39. Nature Publishing Group 10.1038/s41575-020-00366-5

[img] Text
s41575-020-00366-5.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (2MB) | Request a copy

The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the metabolic syndrome and includes the spectrum of liver steatosis (known as nonalcoholic fatty liver) and steatohepatitis (known as nonalcoholic steatohepatitis), which can evolve into progressive liver fibrosis and eventually cause cirrhosis. Although NAFLD is becoming the number one cause of chronic liver diseases, it is part of a systemic disease that affects many other parts of the body, including adipose tissue, pancreatic β-cells and the cardiovascular system. The pathomechanism of NAFLD is multifactorial across a spectrum of metabolic derangements and changes in the host microbiome that trigger low-grade inflammation in the liver and other organs. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear regulatory factors that provide fine tuning for key elements of glucose and fat metabolism and regulate inflammatory cell activation and fibrotic processes. This Review summarizes and discusses the current literature on NAFLD as the liver manifestation of the systemic metabolic syndrome and focuses on the role of PPARs in the pathomechanisms as well as in the potential targeting of disease.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Dufour, Jean-François

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1759-5045

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Thi Thao Anh Pham

Date Deposited:

08 Dec 2020 18:06

Last Modified:

30 Dec 2020 01:33

Publisher DOI:

10.1038/s41575-020-00366-5

PubMed ID:

33093663

BORIS DOI:

10.7892/boris.148100

URI:

https://boris.unibe.ch/id/eprint/148100

Actions (login required)

Edit item Edit item
Provide Feedback